Last reviewed · How we verify
NCT07036601
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
Phase 2 trial testing THDBH120 injection in Overweight or Obese in 276 participants. Currently enrolling.
13 February 2026
Quick facts
| Lead sponsor | Tonghua Dongbao Pharmaceutical Co.,Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 276 |
| Start date | 6 January 2025 |
| Primary completion | 13 February 2026 |
| Estimated completion | 11 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- THDBH120 injection — full drug profile →
- Placebo of THDBH120 injection — full drug profile →
Conditions studied
- Overweight or Obese — all drugs for Overweight or Obese →
Sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Overweight or Obese. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07036601
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of THDBH120 injection
Trials testing the same drug.
- NCT06951945 — Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patie · Phase 1 · completed
- NCT07020949 — Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patie · Phase 1 · completed
Other recruiting trials for Overweight or Obese
Currently open trials in the same condition.
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07340125 — Pistachio Snacking and Metabolic Flexibility · NA · recruiting
- NCT06859853 — A Study to Evaluate MWN109 Injection in Healthy Subjects · Phase 1 · recruiting
- NCT06628362 — A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus · Phase 2 · active not recruiting
Other Tonghua Dongbao Pharmaceutical Co.,Ltd trials
Trials by the same sponsor.
- NCT06951945 — Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patie · Phase 1 · completed
- NCT07020949 — Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patie · Phase 1 · completed
- NCT06449703 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects · Phase 1 · recruiting
- NCT07257627 — Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites · Phase 1 · completed
- NCT06744868 — A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07036601 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tonghua Dongbao Pharmaceutical Co.,Ltd
- Last refreshed: 25 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07036601.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing